



Rating Release

December 19, 2007
Mumbai

CRISIL reaffirms CADILA HEALTHCARE LIMITED's ratings

Rs.300 Million Non-Convertible Debenture Programme	AA+ /Stable (Reaffirmed)
Rs.600 Million Commercial Paper Programme	P1+ (Reaffirmed)

CRISIL's ratings on Cadila Healthcare Ltd's (Cadila Healthcare's) debt instruments continue to reflect the company's established position in the domestic formulations market. The ratings are further strengthened by Cadila Healthcare's increasing revenues from contract manufacturing, initiatives to expand into the international generics markets, and robust profitability. These strengths are, however, partially offset by the company's limited geographic diversity.

Cadila Healthcare, the fifth-largest player in the domestic formulations market, has a strong position in key therapeutic segments such as cardiovascular, gastrointestinal, female healthcare, pain management, and anti-infectives. In 2006-07 (refers to financial year, April 1 to March 31), the company entered into 12 contract manufacturing arrangements with international companies, taking the cumulative number of contracts signed to 23, with a peak revenue potential of USD33.9 million. The company's business prospects are supported by its initiatives to augment its presence in the regulated generics markets in Europe and the US. Cadila Healthcare enjoys strong profitability with consolidated net profit margins of about 13 per cent in 2006-07 and a high return on capital employed of around 23 per cent. The company's export focus, new product launches, and cost-cutting initiatives drive its healthy revenues and profitability.

Cadila Healthcare derives almost 71 per cent of its revenues from the domestic market and any changes in domestic regulations, pricing, and taxation could have a significant impact on the company's financial profile.

Outlook: Stable

In CRISIL's opinion, Cadila Healthcare's diversified product profile and operational efficiencies provide stability to its credit profile. The outlook could be revised to 'positive' if the company's growth initiatives lead to a significant correction in its capital structure and debt protection measures. Conversely, the outlook could be revised to 'negative' if the business initiatives do not fructify, or debt-funded acquisitions further skew the capital structure.

About Cadila Healthcare

Cadila Healthcare, the flagship company of the Zydus Cadila group, is the fifth-largest Indian pharmaceutical company, and its diverse portfolio includes pharmaceuticals, diagnostics, herbal products, skin care products, and over-the-counter products. The company has a strong manufacturing base, comprising nine facilities, each identified for a specific target market. The formulation plant at Moraiya and the bulk activity plants at Ankleshwar and Vadodara (Banyan Chemicals) are approved by the United States Food and Drug Administration. During 2006-07, Cadila Healthcare set up a greenfield formulation facility at Sikkim and during 2005-06 a new plant at Baddi, Himachal Pradesh, both of which are eligible for tax holidays. In 2006-07, the company reported a net profit of Rs.2.4 billion on sales of Rs.17.9 billion, as against a net profit of Rs.1.5 billion and sales of Rs14.5 billion in the previous year. For the six months ended September 30, 2007 the company reported a net profit of Rs. 1.6 billion on sales of Rs. 11.8 billion, as against the net profit of Rs. 1.3 billion on sales of Rs. 9.2 billion in the corresponding period of the

previous year.

Media Contact	Analytical Contacts	CRISIL Rating Desk
Ramya Krishnan Anil Head, Market Development & Communications CRISIL Phone: +91-22-6758-8051 Mobile: +91 98203 42671 Facsimile: +91-22-6758-8088 Email: RamyaKA@crisil.com	S Venkataraman Director, Corporate and Government Ratings - CRISIL Ratings Tel: +91-22-6691 3119 E-mail: svenkat@crisil.com John Joseph Head, Corporate and Government Ratings - CRISIL Ratings Tel: +91-22-6691 3133 E-mail: jjoseph@crisil.com	Tel: +91-22-6691 3047 / 6691 3064 Email: CRISILratingdesk@crisil.com

Note:

This Rating Release is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating release may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution of its Releases for consideration or otherwise through any media including websites, portals etc.

CRISIL is India's leading Ratings, Research, Risk and Policy Advisory company. CRISIL leverages its core strengths of credibility and analytical rigour to deliver opinions and solutions, that help clients mitigate and manage their business and financial risks, make markets function better, and help shape public policy. For more information, visit www.crisil.com.

Disclaimer: A CRISIL rating reflects CRISIL's current opinion on the likelihood of timely payment of the obligations under the rated instrument and does not constitute an audit of the rated entity by CRISIL. CRISIL ratings are based on information provided by the issuer or obtained by CRISIL from sources it considers reliable. CRISIL does not guarantee the completeness or accuracy of the information on which the rating is based. A CRISIL rating is not a recommendation to buy, sell or hold the rated instrument; it does not comment on the market price or suitability for a particular investor. All CRISIL ratings are under surveillance. Ratings are revised as and when circumstances so warrant. CRISIL is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of this product. For the latest rating information on any instrument of any company rated by CRISIL, please contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (+91 22) 6691 3001 - 09.